China Archives

News and Trends 2 Dec 2022

Tris Pharma and Pediatrix Therapeutics extend partnership for ADHD portfolio

Tris Pharma, Inc announced today (December 2) that they have expanded their partnership allowing Pediatrix Therapeutics to receive exclusive rights to commercialize its entire FDA-approved ADHD portfolio as well as ADHD pipeline products in China. Tris says it has a robust portfolio of FDA-approached products for the treatment of attention deficit/hyperactivity disorder (ADHD) and a pipeline of treatments […]

December 2, 2022 - 2 minutesmins - By Liza Laws

News and Trends 2 Dec 2022

Full-Life Technologies acquiring Focus-X Therapeutics

Full-Life Technologies, a global radiotherapeutics company, is acquiring New Jersey-based Focus-X Therapeutics, a company developing targeted radiopharmaceuticals to treat cancer based on peptide engineering technology. The acquisition expands Full-Life’s pipeline, including two compounds nearing clinical trials, provides a second innovative peptide focused discovery platform, and leverages its radiotechnology manufacturing and logistics platforms to advance compounds […]

December 2, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 25 Nov 2022

XtalPi and CK Life Sciences partner on tumor vaccine R&D

XtalPi has entered into a strategic collaboration with CK Life Sciences, a member of the CK Hutchison Group. The goal is to jointly develop a novel artificial intelligence (AI) tumor vaccine R&D platform. This will improve the discovery and design capabilities of tumor vaccines and accelerate development of more vaccine types. According to public information, […]

November 25, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 24 Nov 2022

FDA gives IND approval for Ascletis Covid drug

Ascletis Pharma Inc. has revealed that the U.S. Food and Drug Administration (FDA) has approved the investigational new drug (IND) application of ASC11, an oral inhibitor drug candidate targeting 3-chymotrypsin like protease (3CLpro) for Covid-19. The FDA has approved Ascletis to study the safety, tolerability and pharmacokinetics of ASC11 at various doses in healthy subjects […]

November 24, 2022 - 2 minutesmins - By Jim Cornall

More News! 18 Nov 2022

Triastek cleared for 3D printed medicine treatment of ulcerative colitis

Triastek, Inc. has received clearance for its Investigational New Drug (IND) application from the United States Food and Drug Administration (FDA) to initiate clinical studies of the 3D printed medicine, T21, a potential treatment for ulcerative colitis. “We are excited to receive IND clearance to begin clinical trials of this potentially transformative treatment for patients,” […]

November 18, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 17 Nov 2022

Ascletis announces IND approval for treatment of advanced solid tumors

Ascletis Pharma has announced the approval of the investigational new drug (IND) application by China National Medical Products Administration (NMPA). The approval is for an in-house developed oral PD-L1 small molecule inhibitor prodrug, ASC61, for the treatment of advanced solid tumors. The ASC61 phase 1 dose escalation study is ongoing in the U.S. IND approval […]

November 17, 2022 - 2 minutesmins - By Liza Laws

News and Trends 17 Nov 2022

VISEN growth hormone deficiency trial results announced

VISEN Pharmaceuticals has published detailed clinical data from its pivotal phase 3 study of lonapegsomatropin, a long-acting prodrug of unmodified somatropin being investigated as a once-weekly injection in children with growth hormone deficiency (GHD) in China. The data showed that lonapegsomatropin demonstrated an annualized height velocity (AHV) of 10.66 cm/year compared to 9.75 cm/year for […]

November 17, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 16 Nov 2022

Ascletis’ monkeypox tablet receives IND approval from the FDA

A drug to treat monkeypox from Ascletis Pharma has had its investigational new drug (IND) application approved by the U.S Food and Drug Administration (FDA). The FDA made its decision based on the available data, which was 800 mg ASC10 taken twice a day, and Ascletis can now go ahead with a phase 1b clinical […]

November 16, 2022 - 3 minutesmins - By Liza Laws

News and Trends 15 Nov 2022

Biotheus enters agreement with Hansoh Pharma for bispecific antibody

Biotheus Inc., a clinical-stage biotech company focused on the discovery and development of biologics for oncology and inflammatory diseases, has entered into a collaboration agreement with Hansoh Pharmaceuticals, for Biotheus’ EGFR/MET bispecific antibody (also known as PM1080) in China, Hong Kong, Macao and Taiwan. Under the terms of the agreement, Hansoh will be granted by […]

November 15, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 14 Nov 2022

Nuance Pharma’s RSV vaccine cleared for trial in China

Nuance Pharma says China’s Center for Drug Evaluation (CDE) has approved its investigational new drug (IND) application supporting its pivotal phase III clinical trial of MVA-BN RSV vaccine against respiratory syncytial virus (RSV) in adults in China. MVA-BN RSV is being developed for the prevention of RSV in older adults. The vaccine incorporates five distinct RSV […]

November 14, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 14 Nov 2022

HUTCHMED announces positive gastric cancer study results in China

HUTCHMED (China) Limited has announced initial results from FRUTIGA, a phase III study of fruquintinib combined with paclitaxel in 703 Chinese patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma. The trial was positive, having met one of the primary endpoints of statistically significant improvement in progression-free survival (PFS), which is clinically meaningful. The other […]

November 14, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 10 Nov 2022

Ascentage Pharma gets Chinese approval for solid tumor study

Ascentage Pharma says its novel inhibitor of the embryonic ectoderm development (EED) protein, APG-5918, has been approved by the Center for Drug Evaluations (CDE) of China National Medical Products Administration (NMPA) to enter a phase I study in patients with advanced solid tumors or hematologic malignancies. Following the recent clearance for the study in the […]

November 10, 2022 - 3 minutesmins - By Jim Cornall

Resources

Categories

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

China

Tris Pharma and Pediatrix Therapeutics extend partnership for ADHD portfolio

Full-Life Technologies acquiring Focus-X Therapeutics

XtalPi and CK Life Sciences partner on tumor vaccine R&D

FDA gives IND approval for Ascletis Covid drug

Triastek cleared for 3D printed medicine treatment of ulcerative colitis

Ascletis announces IND approval for treatment of advanced solid tumors

VISEN growth hormone deficiency trial results announced

Ascletis’ monkeypox tablet receives IND approval from the FDA

Biotheus enters agreement with Hansoh Pharma for bispecific antibody

Nuance Pharma’s RSV vaccine cleared for trial in China

HUTCHMED announces positive gastric cancer study results in China

Ascentage Pharma gets Chinese approval for solid tumor study

Subscribe to our newsletter to get the latest biotech news!

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!